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Abstract
Background
Cotrimoxazole (CTX) preventive therapy (CPT) reduces opportunistic infections and malaria
in HIV-infected patients. In Africa, policies on sustained CPT during antiretroviral therapy
(ART) differ between countries. We assessed the safety of discontinuing CPT in stable
patients on ART in Uganda.
Methods
COSTOP was a double-blind placebo-controlled trial. Patients aged�18 years, on CPT,
and stable on ART (CD4 counts�250 cells/μL); were randomised to daily oral placebo
(PLC group) or cotrimoxazole 960 mg/tablet (CTX group). Co-primary outcomes were: (i)
time to first cotrimoxazole-preventable infection, with non- inferiority of PLC defined as the
upper one-sided 95% confidence limit of the adjusted hazard ratio(aHR)�1.25; and (ii) time
to first grade 3/4 haematological adverse event.
Findings
2180 subjects (1091 PLC; 1089 CTX) were enrolled. 932 PLC and 943 CTX completed the
trial after 12 months minimum follow up. Ninety-eight participants (59 PLC; 39 CTX) experi-
enced 120 cotrimoxazole- preventable events, mainly bacterial pneumonia (72 events, 4
deaths PLC); (48 events, 2 deaths CTX). The aHR for time to first event was 1.57 (upper
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one-sided 95% confidence limit 2.21) in per protocol population (similar results in ITT popu-
lation). 551 participants (318 CTX; 233 PLC) experienced 1043 haematological adverse
events (616 CTX; 427 PLC). Time to the first adverse event, mainly neutropenia, was
shorter in the CTX group (aHR 0.70 95%CI 0.59–0.82; log-rank χ2 = 18.08; P<0.0001). 362
(276 PLC, 86 CTX) participants experienced at least one episode of confirmed clinical
malaria (P<0.0001).
Interpretation
In ART stable patients with CD4 counts�250 cells/μL, continued CPT significantly reduces
risk of severe bacterial infections and protects against malaria, while discontinuing CPT
reduces haematological adverse events.
Introduction
Primary cotrimoxazole preventive treatment (CPT) has been recommended as part of the min-
imum package of care for people living with HIV/AIDS (PLHIV) in Africa since 2001 [1], a
practice supported by clinical trials among antiretroviral naïve patients with advanced HIV
disease; which demonstrated that CPT significantly reduces HIV related mortality, bacterial
infections, malaria and related hospital admissions.[2,3]
Subsequent to wide spread availability of antiretroviral therapy (ART), survival and
immune function of PLHIV in low and middle income countries have significantly improved,
[4] making the added value of sustained CPT alongside ART unclear. This is an important
consideration since the CPT intervention represents a substantial increase in overall costs of
HIV care programs. [5] In addition to placing a higher pill burden on ART treated patients,
cotrimoxazole is associated with haematological toxicity and other unwanted effects such as
allergic reactions, photosensitivity, interstitial nephritis and cross-resistance with some of the
antimalarial drugs in frequent use.[6–9]
In high-income countries, primary CPT is not continued among patients on ART after
CD4 count reconstitution to 200 cells/μL or once HIV viraemia becomes undetectable.[8,10]
In low income countries, policies on CPT during ART differ; with a majority of national guide-
lines recommending discontinuation of CPT following CD4 count reconstitution thresholds
that range from 200–500 cells/μL and some countries still recommending that CPT during
ART be continued indefinitely.[11]
Based on observational studies [12–14] and unblinded randomised trials on discontinuing
CPT among patients on ART,[15,16] the World Health Organisation (WHO) in 2014 issued a
recommendation that CPT may be discontinued in adults on ART following HIV virologic
suppression, but that cotrimoxazole prophylaxis should be continued in settings where bacte-
rial infections and malaria are highly prevalent.[17] However, the safety and risk benefits of
stopping CPT in ART stable patients in low and middle countries have not been assessed in a
double blind randomised controlled trial.
We report on the results of a double blind placebo controlled trial in Uganda to investigate
the safety of discontinuing CPT and potential benefits in reduced cotrimoxazole-associated
toxicity. Information on the design of this trial and malaria-specific findings of discontinuing
CPT have been reported previously [18,19].
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Methods
Study design
The safety of discontinuing CPT was assessed by determining whether the experimental (pla-
cebo) group was non-inferior to the control group (in which CPT was continued), with respect
to the incidence of cotrimoxazole (CTX) preventable infections. The potential benefits of dis-
continuing CPT were studied by comparing rates of haematological adverse events in both
groups, testing for superiority of the placebo group. The trial was conducted in two research
clinics of the MRC/UVRI and LSHTM Uganda Research Unit, located in a district hospital in
Entebbe town and a regional referral hospital in Masaka town. We obtained approvals from
the Research Ethics Committee of the Uganda Virus Research Institute, the Uganda National
Council for Science and Technology and the Uganda National Drug Regulatory Authority.
Details of the study protocol have been reported earlier[18,19] The trial was registered
(ISRCTN44723643).
Participants
Patients were recruited from HIV care centres situated near-by where they continued to
receive their ART. They were eligible if aged�18 years (before protocol amendment of
December 2011, age limit was 18 to 59 years), had been on ART and daily CPT for at least 6
months, had a confirmed CD4 count of�250 cells/μL, no contraindication to taking CTX and
having provided informed consent. Patients were excluded if they had an acute illness, history
of grade 3 or 4 anaemia, neutropenia or thrombocytopenia, were receiving secondary CPT for
a previous opportunistic infection or in first trimester pregnancy. All participants gave written
informed consent for screening procedures and for recruitment, with independently witnessed
consent if not literate.
Randomisation and masking
Patients were randomised 1:1 to receive placebo (PLC) or active CTX. They were requested to
take trial drugs as prescribed, submit any previous CTX supply still in their possession, and
not use CTX from other sources. A randomisation schedule was developed using random per-
muted blocks with varying block size. We used five different block sizes of 8, 10, 12, 14 and 16.
Separate randomisations were performed in four strata defined by study site (Entebbe or
Masaka) and baseline CD4 count (250–499 cells/μL or�500 cells/μL). Trial drugs (CTX or
placebo) sufficient for the period between scheduled study visits, were packed by independent
supervised assistants, using identical containers labelled with trial numbers that corresponded
to the randomisation register. At enrolment, clinicians entered the details of each participant
in the next available row of the enrolment register, stratified by CD4 count. The trial number
corresponding to that row was used on all trial documents of that patient and to identify the
pre-packed study medication. Participants and investigators remained blinded to treatment
allocation throughout. Only an independent statistician had access to the randomisation
codes. At the end of follow up, exit interviews were conducted to determine whether partici-
pants had adhered to the protocol with respect to their treatment allocation.[20]
Procedures
Consenting patients were screened 2 to 4 weeks before enrolment. Their medical history was
recorded, and a physical examination, full blood count, CD4 count and urine pregnancy test
(in women of reproductive age) performed. At enrolment, all were requested to continue the
ART regimen provided by their HIV care provider. They received pre-labelled study drug as
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described above, comprising one oral tablet of 960mg CTX daily (CTX group) or one oral tab-
let daily of a matching placebo (PLC group). Study drugs had been obtained from CIPLA Ltd
India. For ethical reasons and to limit the confounding effect of an imbalance in the routine
use of effective malaria preventive interventions, at enrolment and once during follow-up each
patient was issued with an insecticide treated bed net (ITN) and instructed to sleep under it.
Follow up assessments, conducted by study nurses and doctors were scheduled monthly for
the first 3 months to assess health and adherence to medications and then 3-monthly thereaf-
ter. At each visit clinical information was recorded, and a blood slide examination for malaria
parasites and full blood count performed. CD4 counts were performed every 6 months after
enrolment. Patients received a new supply of study drug every 3 months. Adherence to study
drug and to ART was assessed at each clinic visit using pill counts and self-report question-
naires, and reported ITN use recorded. Patients were also encouraged to report to their study
clinic whenever they were ill. Enrolment took place between 20 January 2011 and 21 March
2013. Trial duration was three years (2011–2014). Patients were followed for a minimum of 12
and a maximum of 36 months. At study exit, all patients were prescribed open-label cotrimox-
azole as prophylactic treatment in keeping with national guidelines and continued their usual
ART.
Outcomes
The two co-primary outcome measures were: (i) time to the first CTX-preventable event or
CTX-preventable death and; (ii) time to the first grade 3 or 4 haematological adverse event.
We defined cotrimoxazole preventable clinical events based on biological plausibility, as those
infections listed in the WHO surveillance clinical classification of HIV-related disease in
adults,[21] against which cotrimoxazole has known biological activity, (see S1 Appendix.
Cotrimoxazole preventable events). An independent end-point review committee (ERC), who
were blinded to treatment allocation, reviewed all reported clinical events and deaths and adju-
dicated whether these fulfilled WHO surveillance clinical staging definitive or presumptive
diagnostic criteria[21] and whether they could be defined as a CTX-preventable event. Labora-
tory tests for haematologic toxicity were performed at the MRC/UVRI laboratories in Entebbe.
Results were graded according to the USA National Institute of Allergy and Infectious Dis-
eases—Division of AIDS severity grading table, [22] and referred for assessment to the ERC if
associated with a significant clinical event such as septicaemia. Secondary outcomes included
the incidence of all CTX-preventable events, all-cause mortality, hospitalisations, asymptom-
atic and symptomatic malaria episodes confirmed by a positive parasitaemia blood slide, seri-
ous adverse events, the mean changes in CD4 count and other haematological parameters 48
weeks after enrolment, as well as adherence to ART, trial drug and ITN use.
Statistical analysis
The sample size was based on assumptions described elsewhere.[18] In brief the assumed rate
of CTX-preventable clinical events in the control group would be 10 per 100 PYO, based on an
analysis of event rates from the DART trial among participants with confirmed CD4 count
above 250 cells/μL[23] and loss to follow up rate would be 4% per year[23]. Recruiting 2000
participants was expected to provide 80% power, at the 5% level of significance (one-sided for
non-inferiority), to determine non-inferiority (upper limit of the one-sided 95% CI for the
aHR<1.25) of CPT discontinuation with respect to cotrimoxazole-preventable clinical events.
For the haematological co-primary end-point, the sample would have 80% power to detect a
50% reduction in the expected rate of grade 3 or 4 haematological events.
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In May 2012 the trial steering committee and regulatory bodies permitted recruitment of
an additional 180 participants in order to accommodate a sub-study on microbial transloca-
tion and immune activation in the COSTOP trial population (results to be reported else-
where). Data were double-entered and verified in MS Access (Microsoft, Redmond,
Washington, USA) and analysed using Stata 13 (Stata Corp, College Station, Texas, USA).
Two data sets were generated for the efficacy analysis, i.e. for per protocol (PP) and intention
to treat (ITT) populations. Demonstration of non-inferiority of the PLC group with respect to
CTX-preventable events requires that it can be shown in both the primary PP analysis and in
the ITT populations since non-adherers in the ITT population may dilute any real treatment
related differences. On the other hand, the PP population may be prone to selection bias, par-
ticularly if loss to follow up was differential between trial arms with regard to the risk for CTX-
preventable events.[24] The ITT data set comprised all subjects who took at least one dose of
study drug and for whom follow-up was assessed at least once. Participants remained in the PP
population as long as they reported taking at least 80% of trial drugs since their last visit. For
the co-primary endpoint on haematological events and for all secondary endpoints, the analy-
sis was based on the ITT population.
The non-inferiority of placebo to CTX with respect to CTX-preventable events would be
demonstrated if the upper limit of the one-sided 95% confidence interval of the hazard ratio
(HR) for placebo relative to CTX was no greater than 1.25 (a relative increase of 25%). In the
event that non-inferiority was not shown, an analysis would be carried out on the ITT popula-
tion to assess whether continuing CTX was superior to PLC with respect to CTX-preventable
events. Superiority of placebo to CTX with respect to haematological adverse events would be
demonstrated if there was a statistically significant reduction in time to occurrence of the first
grade 3 or 4 haematological event. All time to event analyses were carried out by fitting Cox
proportional hazards regression models adjusting for study site and CD4 stratum only.
Changes in CD4 and other haematological parameters were carried out by fitting linear regres-
sion models to the week 48 result (subject to a transformation such as logarithmic or square
root in the event of severe heteroscedasticity). Adjustment was made for the baseline result
(similarly transformed if appropriate), study site and the actual number of days between the
readings closest to baseline and week 48 respectively. Thus week 48 mean CD4, white blood
cell (WBC) and neutrophil counts were subjected to a natural logarithmic transformation and
week 48 mean platelet count to square root transformation. For each haematological parame-
ter, its marginal mean was estimated from the fitted regression model with the baseline of the
parameter and actual number of days between baseline and 48 week assessment set at their
mean values, averaged over the two sites, and the parameter back-transformed (for example
WBC was subject to an exponential transformation). An independent data monitoring com-
mittee (IDMC) conducted 5 interim analyses using the Peto-Haybittle approach during the
trial, that is only a probability of equal to, or less than 0.001 at interim analysis would be con-
sidered grounds for recommending early stopping. On each occasion the IDMC recom-
mended that the trial should continue as planned. As is standard when using the Peto-
Haybittle approach [25], no adjustment was made to the significance level used for the final
analysis.
Results
A total of 2944 patients were screened, of whom 2180 (75%) were enrolled. Details of screen
failures are presented in the trial profile (Fig 1). The main reasons for non-enrolment were low
CD4 count, grade 3 or 4 neutropenia and failure to return after screening. Of the 2180 partici-
pants enrolled, 1089 were allocated to CTX and 1091 to PLC. Five patients did not return after
Safety of discontinuing cotrimoxazole prophylaxis in HIV-infected adults on antiretroviral therapy in Uganda
PLOS ONE | https://doi.org/10.1371/journal.pone.0206907 December 31, 2018 5 / 16
Fig 1. Trial profile.
https://doi.org/10.1371/journal.pone.0206907.g001
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enrolment. The remaining 2175 participants contributed 4806.4 person years of follow-up to
the ITT analysis, and 1875 participants completed the trial. A total of 2161 participants con-
tributed 4132.6 person years of follow-up to the PP analysis (Fig 1). For the ITT population,
the median duration of follow-up was 2.3 years (IQR 1.2–2.8) for CTX and 2.1 years (IQR 1.1–
2.8) for PLC participants. Baseline characteristics were similar between trial arms (Table 1).
Slightly more participants were enrolled at Masaka (1178) than at Entebbe (1002). Almost 75%
of participants were women, reflecting the gender distribution of patients registered at HIV
care centres. About two thirds had been in WHO surveillance clinical stage 3 or 4 at the time
of ART initiation. The median duration on ART was 47 months and median CD4 cell count at
study entry was 518 cells/μL (IQR 410–688). Two thirds of participants reported that they slept
under a mosquito net.
Primary outcome (i)
In the PLC group 59 participants (5.4%) experienced a total of 72 events (including 4 deaths)
compared to 39 (3.6%) participants in the CTX group who experienced a total of 48 events
(including 2 deaths). Fig 2 shows a Kaplan-Meier plot of the time to the first CTX-preventable
event by treatment group for the PP population (Fig 2). The results of a survival analysis for
both the PP and ITT populations are summarized in Table 2, including the results of fitting a
Cox regression model to the comparison of the two trial groups, adjusting for site and CD4
stratum. We failed to demonstrate non-inferiority of CPT discontinuation; in both the PP and
ITT populations, the stratified log-rank test provided strong evidence that the risk of CTX-pre-
ventable events was higher in the PLC group than in the CTX group. For example, for the PP
population the log-rank test was χ2 = 4.77; (P = 0.029). This was confirmed by the results of
the Cox regression model: the adjusted hazard ratio (aHR) was 1.57 (upper one-sided 95%
confidence limit 2.21) (Fig 2). The upper one-sided 95% confidence limit for the aHR of 2.21
exceeded the non-inferiority cut-off of 1.25. Similar results were obtained for the ITT popula-
tion. There was some evidence (P = 0.057) of an interaction between CD4 count stratum and
trial allocation. A sub-group analysis showed that the effect of CTX prophylaxis on CTX-pre-
ventable events was stronger in the higher CD4 count stratum (aHR 2.35; P = 0.006) than in
the lower CD4 count stratum (aHR 1.07; P = 0.80) (Table 2). However, in both strata the
upper one-sided 95% confidence limit for the aHR for PLC vs. CTX exceeded the non-inferior-
ity cut-off of 1.25. The ITT analysis produced similar results. Based on these results, the com-
puted number needed to treat over one year in order to prevent one WHO staging CTX-
preventable clinical event is 113. The commonest non-fatal CTX-preventable events were
bronchopneumonia (20 CTX, 33 PLC) and recurrent bacterial upper respiratory tract infec-
tions (5 CTX, 4 PLC). Categorisation of CTX-preventable events by treatment group is pro-
vided in a table (S1 Table. Non-fatal cotrimoxazole preventable events by treatment group).
Primary outcome (ii)
A total of 551 participants (318 CTX, 233 PLC) experienced a total of 1043 haematological
adverse events (616 CTX, 427 PLC). An analysis of time to the first event showed a significant
excess in the CTX group (log-rank χ2 = 18.08; P<0.0001) (Fig 3). This was confirmed by fit-
ting a Cox proportional hazards regression model, adjusting for CD4 stratum and study site.
The aHR for PLC vs. CTX was 0.70, (95% CI 0.59; 0.82). The excess was mainly due to grade 3
or 4 neutropenic events, with 28.2% of participants in the CTX group experiencing this at least
once compared to 19.3% in the PLC group. The trial thus demonstrated the superiority of CPT
discontinuation over continued CPT with respect to the primary haematological outcome.
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Table 1. Baseline characteristics.
Variable Category CTX (n = 1089) Placebo (n = 1091)
Site Entebbe 501 (46.0%) 501 (45.9%)
Masaka 588 (54.0%) 590 (54.1%)
CD4 stratum < 500 572 (52.5%) 570 (52.2%)
� 500 517 (47.5%) 521 (47.8%)
CD4 at randomization Median (IQR) 518 (410–696) 519 (411–682)
CD4 at randomization (grouped) 250–349 102 (9.4%) 142 (13.0%)
350–499 414 (38.0%) 370 (33.9%)
500 plus 573 (52.6%) 578 (53.0%)
Sex Male 286 (26.3%) 283 (25.9%)
Female 803 (73.7%) 808 (74.1%)
Age Mean (s.d.) 41.0 (8.0) 40.7 (8.3)
Median (IQR) 41 (36–46) 40 (35–47)
Weight (kg) Mean (s.d.) 58.5 (10.7) 59.0 (10.8)
BMI (kg/m2) Mean (s.d.) 22.2 (3.8) 22.5 (4.2)
WHO stage I 54 (5.0%) 50 (4.6%)
II 291 (26.9%) 303 (28.0%)
III 621 (57.4%) 623 (57.6%)
IV 115 (10.6%) 105 (9.7%)
Education level None 111 (10.2%) 113 (10.4%)
Primary 649 (59.6%) 660 (60.5%)
Secondary 275 (25.3%) 268 (24.6%)
University / vocational 53 (4.9%) 50 (4.6%)
Marital status Married / cohabiting 473 (43.5%) 465 (42.6%)
Separated etc. 576 (52.9%) 577 (52.9%)
Single never married 39 (3.6%) 49 (4.5%)
Disclosed HIV status to partner Yes 522 (85.6%) 520 (82.9%)
No 88 (14.4%) 107 (17.1%)
Months on ART Median (IQR) 48 (27–66) 47 (26–65)
Initial ART regimen AZT / 3TC / NVP 521 (47.8%) 504 (46.2%)
AZT / 3TC / EFZ 76 (7.0%) 74 (6.8%)
d4T / 3TC / NVP 321 (29.5%) 348 (31.9%)
d4T / 3TC / EFZ 33 (3.0%) 27 (2.5%)
TDF / 3TC(FTC) / NVP 74 (6.8%) 73 (6.7%)
TDF / 3TC(FTC) / EFZ 23 (2.1%) 25 (2.3%)
AZT / 3TC / TDF 22 (2.0%) 31 (2.8%)
Other 13 (1.2%) 7 (0.6%)
Missing 6 (0.6%) 2 (0.2%)
Current regimen AZT / 3TC / NVP 693 (63.6%) 716 (65.6%)
AZT / 3TC / EFZ 131 (12.0%) 114 (10.4%)
TDF / 3TC(FTC) / NVP 133 (12.2%) 134 (12.3%)
TDF / 3TC(FTC) / EFZ 53 (4.9%) 50 (4.6%)
AZT / 3TC / TDF 9 (0.8%) 8 (0.7%)
Any PI 42 (3.9%) 44 (4.0%)
Other 16 (1.5%) 16 (1.5%)
Missing 12 (1.1%) 9 (0.8%)
Any ART switch prior to enrolment Yes 497 (46.4%) 494 (45.7%)
(Continued)
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Secondary Outcomes
Results of secondary outcomes are shown in Table 3. There was no evidence of a difference in
all-cause mortality between trial groups: 19 deaths in the CTX group (1.8%) and 18 in the PLC
group (1.7%) (log-rank χ2 = 0.01; P = 0.91). Causes of death are listed in a table (S2 Table.
Causes of death)
More patients in the PLC group (97 participants, 8.9%, 125 events) experienced at least one
WHO surveillance clinical stage 2,3 or 4 event or death than participants in the CTX group (77
participants, 7.1%, 99 events), a non-significant difference (log-rank χ2 = 2.53; P = 0.11 for
time to first event). In total 362 (276 (25.3%) PLC, 86 (7.9%) CTX) participants experienced at
least one episode of confirmed clinical malaria (P<0.0001). A detailed analysis of malaria
Table 1. (Continued)
Variable Category CTX (n = 1089) Placebo (n = 1091)
When did you last miss ARVs? Last week 17 (1.6%) 13 (1.2%)
1–4 weeks ago 40 (3.7%) 50 (4.6%)
1–3 months ago 41 (3.8%) 40 (3.7%)
>3 months ago 133 (12.4%) 120 (11.1%)
Never 842 (78.5%) 860 (79.4%)
Have you missed CTX in last month? Yes 279 (25.7%) 232 (21.4%)
No 808 (74.3%) 854 (78.6%)
Sleeps under a mosquito net Yes 676 (62.1%) 694 (63.6%)
https://doi.org/10.1371/journal.pone.0206907.t001
Fig 2. Time to first cotrimoxazole-preventable event–PP population.
https://doi.org/10.1371/journal.pone.0206907.g002
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events has been presented elsewhere.[19] More participants in the PLC group than in the CTX
group were admitted to hospital at least once (93; 8.5% vs 53; 4.9%) (P = 0.0004). Reasons for
hospitalisation are listed in a table (S3 Table. Reasons for hospitalisation). The proportion of
participants experiencing at least one serious adverse event, comprising hospital admission,
death or adverse pregnancy outcome (still births or miscarriages), was also higher in the PLC
group (102; 9.4%) than in the CTX group (67; 6.2%) (P = 0.0037). A secondary endpoint was
the rate of all grade 3 or grade 4 haematological adverse events allowing for multiple events per
Table 2. Survival analysis for the PP and ITT populations -number and rates of CTX-preventable events or deaths.
Analysis Placebo group
events
Placebo group Rate/
100pyar (95% C.I.)
CTX group
events
CTX group Rate/
100pyar (95% C.I.)
Stratified log-rank
statistic (P-value)
Adjusted Hazard Ratio
(95% C.I.)�
Per protocol overall 59 2.94 (2.28; 3.79) 39 1.84 (1.34; 2.51) 4.77 (0.029) 1.57 (1.12; 2.21)
Sub-group analysis by
CD4 stratum
CD4<500cells/uL 25 2.4 (1.62; 3.55) 24 2.18 (1.46; 3.25) 0.07 (0.79) 1.07 (0.67; 1.72)
CD4� 500cells/uL 34 3.52 (2.51; 4.93) 15 1.46 (0.88; 2.43) 7.95 (0.005) 2.35 (1.41; 3.91)
ITT overall 59 2.49 (1.93; 3.21) 39 1.6 (1.17; 2.19) 4.5 (0.034) 1.55 (1.03; 2.32)
Sub-group analysis by
CD4 stratum
CD4<500cells/uL 25 2.03 (1.37; 3.00) 24 1.91 (1.28; 2.85) 0.04 (0.85) 1.06 (0.60; 1.86)
CD4� 500cells/uL 34 2.98 (2.13; 4.17) 15 1.27 (0.77; 2.11) 7.86 (0.005) 2.33 (1.27; 4.27)
� The upper limit of the CI gives the upper one-sided 95% confidence limit.
https://doi.org/10.1371/journal.pone.0206907.t002
Fig 3. Time to first grade 3 / 4 haematological adverse event–ITT.
https://doi.org/10.1371/journal.pone.0206907.g003
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participant. An analysis allowing for the clustering of events within participants showed that
participants on PLC were significantly less likely to experience grade 3 or 4 adverse events
than those on CTX (aHR = 0.63; P<0.001). A comparison of mean changes in haematological
parameters after 48 weeks, adjusting for the baseline value of the parameter, study site and
actual number of days between the two measurements, is presented in Table 4. The mean CD4
count at week 48 was significantly higher in the PLC group (P<0.001), as was the total white
blood cell count (P<0.001) and the neutrophil count (P<0.001). There was no significant dif-
ference between trial groups in haemoglobin levels at week 48 (P = 0.44), but some evidence
that the platelet count at week 48 was higher in the CTX group (P = 0.08). Adherence to trial
drug was very similar in the two group with 4.0% of patient-visits in the PLC group reporting
taking less than 80% of trial drug compared to 3.7% in the CTX group (P = 0.58 using robust
standard errors to allow for clustering within participants). The proportion of patient visits at
which participants reported having missed a dose of ART was also similar (3.5% PLC vs. 3.3%
Table 3. Superiority analysis for primary safety outcome and secondary outcomes -ITT population.
Outcome Placebo: participants
with�1 event (%); (no. of
events)
Placebo rate per 100
pyar (95% C.I. time to
1st event)
CTX: participants with
�1 event (%); (no. of
events)
CTX rate per 100
pyar (95% C.I. time
to 1st event)
Stratified log-rank
statistic (P-value)
Adjusted Hazard
Ratio (95% C.I.)
Primary safety
outcome
Grade 3 / 4
haematological adverse
event
233 (21.3%) 427 events 10.6 (9.4; 12.1) 318 (28.9%) 616 events 15.3 (13.7; 17.1) 18.08 (<0.0001) 0.7 (0.59; 0.82)
Secondary outcomes
All-cause mortality 18 (1.7%) 0.73 (0.46; 1.16) 19 (1.8%) 0.76 (0.49; 1.19) 0.01 (0.91) 0.96 (0.50; 1.83)
All WHO stage 2, 3 or
4 events or death
97 (8.9%) 125 events 4.1 (3.4; 5.0) 77 (7.1%) 99 events 3.2 (2.6; 4.0) 2.53 (0.11) 1.28 (0.95; 1.72)
Confirmed clinical
malaria
276 (25.3%) 350 events 13 (11.6; 14.7) 86 (7.9%) 103 events 3.6 (2.9; 4.4) 122.6 (<0.0001) 3.62 (2.84; 4.61)
Hospital admissions 93 (8.5%) 110 events 4 (3.3; 4.9) 53 (4.9%) 65 events 2.2 (1.7; 2.9) 12.36 (0.004) 1.82 (1.30; 2.50)
SAEs 102 (9.4%) 124 events 4.4 (3.6; 5.3) 67 (6.2%) 90 events 2.8 (2.2; 3.5) 8.44 (0.0037) 1.58 (1.16; 2.15)
https://doi.org/10.1371/journal.pone.0206907.t003
Table 4. Comparison of outcomes for continuous laboratory variables at week 48 between treatment groups.
Parameter PLC group CTX group P-value
Baseline CD4 count mean (s.d.) 518.6 (198.8) 519.6 (192.4) <0.001
Week 48 CD4 count mean (s.d.) 531.2 (200.9) 506.3 (188.8)
Marginal mean at week 48 (95% c.i.) 498.2 (491.0; 505.5) 472.4 (466.0; 479.7)
Baseline WBC count mean (s.d.) 4.64 (1.47) 4.61 (1.40) <0.001
Week 48 WBC count mean (s.d.) 4.59 (1.40) 4.24 (1.37)
Marginal mean at week 48 (95% c.i.) 4.39 (4.32; 4.46) 4.05 (3.99; 4.11)
Baseline neutrophil count mean (s.d.) 1.82 (0.89) 1.78 (0.89) <0.001
Week 48 neutrophil count mean (s.d.) 1.87 (0.95) 1.69 (0.90)
Marginal mean at week 48 (95% c.i.) 1.67 (1.63; 1.72) 1.51 (1.47; 1.55)
Baseline Hb count mean (s.d.) 13.36 (1.45) 13.31 (1.47) 0.33
Week 48 Hb count mean (s.d.) 13.36 (1.55) 13.26 (1.51)
Marginal mean at week 48 (95% c.i.) 13.33 (13.27; 13.40) 13.29 (13.24; 13.34)
Baseline platelets count mean (s.d.) 261.5 (68.8) 262.5 (72.9) 0.18
Week 48 platelets count mean (s.d.) 258.2 (74.7) 263.3 (73.2)
Marginal mean at week 48 (95% c.i.) 253.6 (250.1; 257.0) 256.9 (253.6; 260.2)
https://doi.org/10.1371/journal.pone.0206907.t004
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CTX; P = 0.64) as was the proportion of patient visits at which participants reported not having
slept under a mosquito net (5.2% PLC vs. 4.9% CTX; P = 0.42).
A sensitivity analysis was performed by analysing as an end point all CTX-preventable
events or all-cause mortality (i.e. including the 31 deaths deemed not to be CTX-preventable).
The aHR comparing placebo vs. CTX was 1.37 (upper limit of the one-sided 95% CI 1.85).
This upper 95% confidence limit was still beyond the non-inferiority cut-off of 1.25. In a fur-
ther sensitivity analysis in which we excluded 163 participants who admitted to having taken
open label CTX at least once (80 CTX; 83 PLC) the aHR was 1.51 (upper limit of the one-sided
95% CI2.13), and this too did not achieve non-inferiority.
Discussion
Our study evaluated the benefits and risks of discontinuing CPT in HIV infected adults who
are stable on ART in the Uganda. We found that discontinuing CPT significantly increased
the risk of pre-defined CTX-preventable infections, malaria and related hospital admissions.
On the other hand, discontinuing CPT substantially reduced the risk of serious haematologic
adverse events, in particular neutropenia, and did not lead to an increase in mortality.
We did not demonstrate non-inferiority of discontinuing CPT in regard to preventing
severe bacterial infections and malaria and in this respect, our results are in agreement with
earlier open-label studies.[15,16] Cotrimoxazole is a broad spectrum combination antimicro-
bial (trimethoprim/sulfamethoxazole) that is effective against many common bacterial and
protozoal pathogens. Therefore, the effects of continued CPT may have been expected and a
similar effect would probably be observed among HIV negative individuals [26]. However, pri-
mary prophylaxis against bacterial infections with broad spectrum antimicrobials is not gener-
ally recommended for HIV-negative individuals, primarily to guard against widespread
antimicrobial drug resistance; a concern that has previously been raised by others.[27] Further,
cotrimoxazole is not the drug of choice for malaria prophylaxis,[28] although prevention of
malaria in HIV infected patients is an accepted benefit of CPT [17]. It is also important to note
that malaria is still likely to occur among patients on CTX as we also observed a non-negligible
proportion of patients on CTX who still got malaria. This implies that other malaria preventive
strategies should complement CTX prophylaxis. In the context of HIV infection therefore,
CPT offers combined prevention of co-morbid bacterial and protozoal infections as an adjunct
to ART in patients with moderate immune suppression.[29]
We demonstrated that patients who continue CPT have an increased risk of haematological
abnormalities, mainly neutropenia, as well as a lower CD4 count increase under effective ART
compared to those who stopped CPT. Neutropenia is likely to be the result of cotrimoxazole
induced bone marrow suppression, owing to the known antifolate effect of the sulphur moiety
contained in the drug.[6,8] This mechanism may also explain the attenuated increase in CD4
counts that we observed in the cotrimoxazole group (Table 4). This finding supplements previ-
ous studies on CPT among patients on ART which did not report comparisons of the haema-
tological adverse drug effects of cotrimoxazole.[12,15]
The major strengths of our study were the large sample, the double-blind placebo-con-
trolled randomized design, long follow up time and adjudication of clinical outcomes by an
independent ERC. That we evaluated haematological adverse events as a co- primary endpoint
is an additional strength.
Our study had some limitations. The observed rate of CTX-preventable events was much
lower than that assumed in the sample size calculations. This could have reduced the power of
the trial to show non-inferiority with respect to CTX-preventable events. However in this case
we were able to show that continuing CPT was in fact superior to stopping CPT with respect
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to CTX-preventable events, so the study was in fact adequately powered to demonstrate superi-
ority. The PP population was defined by self-reported adherence to study drug. Adherence to
study drug was generally good but not perfect, nor was this the case for the adherence to ART
or bed net use. However, adherence was similar between trial groups, and if at all a lack of
adherence would have diluted the measurable effects of the intervention (use of placebo rather
than CTX). This may have resulted in misclassification, inflating the PP population. The adju-
dication of CTX-preventable effects may also have led to misclassification, diluting measurable
differences between trial groups. This risk was small as clinical observations were carefully
recorded and the ERC comprised highly experienced clinicians. The exit interviews[20]
showed some evidence of open label drug being taken by participants, although results from
the interviews do not suggest that trial results would have been seriously compromised.
Finally, response to ART was determined by CD4 count, and not viral load. As virological fail-
ure on ART may precede CD4 count decline, some patients could have been at a higher risk of
CTX-preventable events than expected. Due to the randomised design, however, this would
not have affected the comparability of trial groups.
The effect of CPT discontinuation was greater in the higher CD4 count stratum. This find-
ing is surprising and we have no clear explanation for it. However, as a point of further
research, one could speculate that an increased expression of CTX-preventable events occurs
at higher CD4 counts. Our data show that the number needed to treat with CPT for one year
in order to prevent one severe bacterial infection was 113. While we showed that continuing
CPT reduced the risk of severe bacterial infections, from a public health point of view this
might not be worthwhile, particularly in settings where there is a low level of such infections,
in patients that have been immunologically reconstituted by ART and / or have adequate man-
agement of these infections. In this respect, our results have important implications for HIV
treatment policy in those countries that still recommend continued CPT alongside ART. A
cost effectiveness analysis based on data from the COSTOP trial is currently ongoing and will
provide added information on the cost benefits of CPT during ART.
In conclusion, continued CPT is beneficial for ART stable HIV infected patients who are at
high risk for severe bacterial infections or malaria. This benefit needs to be weighed against the
risk of haematologic toxicity, and patients eligible for CPT should have access to CD4 and
complete blood count haematological side effects monitoring.
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